BCV, a Paris, France-based medical device company, raised €6M in Series A funding.
The round was led Forepont Capital Partners, with participation from NTI, MEDCO and existing French investors.
The company intends to use the funds to accelerate the development of its range of active mechatronic guidewires, from manufacturing to go-to-market.
Led by Thierry Col, CEO, and Raphaël Blanc, M.D., Chairman, BCV is a medical device company which aims to improve patient outcomes by providing optimized navigation for endovascular procedures. The company achieved its first in-human clinical trial in 2022 at Rothschild Foundation Hospital in Paris and filed a pre-submission application with the FDA.
The patented innovation consists of an actuable guidewire controlled by a smart handle and a generator. The BCV system’s shape-memory alloy technology enables distal tip control improving practitioners’ gestures and demonstrating superior performance over existing advanced actuation technologies.
Originally developed with help from Institute of Intelligent Systems and Robotics (ISIR) at Sorbonne University-CNRS and INSERM (Paris, France), the BCV System is an investigational device and is not available for commercial sale worldwide.
FinSMEs
13/12/2023